Difference between revisions of "Apatinib (Aitan)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Kinase inhibitors" to "") |
m |
||
| Line 5: | Line 5: | ||
*[[Esophageal cancer]] | *[[Esophageal cancer]] | ||
*[[Gastric cancer]] | *[[Gastric cancer]] | ||
| + | *[[Hepatocellular carcinoma]] | ||
==Also known as== | ==Also known as== | ||
| Line 22: | Line 23: | ||
[[Category:Esophageal cancer medications]] | [[Category:Esophageal cancer medications]] | ||
[[Category:Gastric cancer medications]] | [[Category:Gastric cancer medications]] | ||
| + | [[Category:Hepatocellular cancer medications]] | ||
[[Category:CFDA approved drugs]] | [[Category:CFDA approved drugs]] | ||
Revision as of 00:18, 14 June 2021
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Apatinib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.
Diseases for which it is used
Also known as
- Code name: YN968D1
- Generic name: rivoceranib
- Brand name: Aitan